Skip to content

Esketamine for Treatment-Resistant Depression: A Case Series and Literature Review.

Muhammad Abbas, David B Adams, Jack Noto, Renzmark D Vallesteros, Talitha West

Cureus September 2025 DOI: 10.7759/cureus.92165 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Case report series with literature review Peer reviewed
Sample size 4
Population Patients with treatment-resistant depression who had failed electroconvulsive therapy (ECT) at a single Hackensack-Meridian care center
Intervention Esketamine
Topics Depression Esketamine
Keywords Case report series Literature review
Key findings Among four patients with treatment-resistant depression who had failed ECT, three experienced significant symptom improvement with esketamine, but only one achieved effective long-term treatment, with side effects limiting the others. The authors conclude that esketamine is a viable alternative for some patients with TRD, including those who have failed ECT.

Abstract

Management of treatment-resistant depression (TRD) is complex and frustrating for patients, requiring several treatment courses before (or without) achieving remission. This investigation aims to highlight and analyze real-world instances of using esketamine for patients with TRD who have failed electroconvulsive therapy (ECT). Four case reports from a single Hackensack-Meridian care center are described in detail. They, along with a literature review, were then used to drive a narrative discussion on the potential of esketamine as a TRD therapy. Of the four cases analyzed, three patients experienced significant improvement in symptoms. However, largely due to side effects, only one case resulted in effective long-term treatment using esketamine. Given that all four patients previously failed ECT, these results are encouraging. Even a humble success rate may inspire hope in a patient population that is largely considered intractable using current methodology. This study found that esketamine is a viable alternative for some patients suffering from TRD. This even remains true in some of our patients who have failed ECT - one of the more effective, more aggressive therapies for TRD.

Explore topics